Cholecalciferol Intervention to Prevent Respiratory Infections Study (CIPRIS)
CIPRIS is a randomised controlled trial of cholecalciferol (vitamin D) as an intervention against acute respiratory tract infections (RTIs). In addition to its well-recognised role in bone health, vitamin D has been found to play a crucial role in the proper function of the immune system, both adaptive and innate. There is increasing evidence to suggest that the increase in acute infections, particularly RTIs during the winter months is because of the lower ambient UV during this time of year, reducing production of vitamin D.
In the CIPRIS trial, we recruited a cohort of 32 healthy young adults (18-55yo) and randomised them to 20,000 IU/week cholecalciferol vs. placebo for 17 weeks. Participants were asked to complete a quick (~5 min) online questionnaire (link below) to report the occurrence of any infection symptoms, and attend a weekly clinic here at MS1 to have a nasal swab, complete a short questionnaire (10-15 min) and receive their weekly treatment allocation.
The study began seeing participants in May 2012 and completed follow-up in October 2012. Samples are presently being analysed for relevant factors and analysis of study data is in progress.
For further information please email: cipris.trial@utas.edu.au
Staff
Senior Members
- Associate Professor Leigh Blizzard
- Professor Bruce Taylor
Members
- Assoc Professor Ingrid van der Mei
Team Leaders
- Dr Steve Simpson Jr.
Team Members
- Dr Niall Stewart
- Carol Hurst (Administrative Officer)